NantKwest

NantKwest

Founded 2002

Culver City, United States 44 employees Post-IPO Equity Total: $103.50M Biotechnology, Health Care +1

NantKwest (NASDAQ: NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$39.00M	1	Patrick Soon-Shiong	26 Mar 2019
Post IPO Equity	$17.00M	-		05 Aug 2015
Post IPO Equity	$47.50M	-		23 Dec 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$39.00M

Patrick Soon-Shiong

26 Mar 2019

Post IPO Equity

$17.00M

05 Aug 2015

Post IPO Equity

$47.50M

23 Dec 2014

FAQ About NantKwest

NantKwest was founded in 2002.

NantKwest is headquartered in Culver City, United States.

NantKwest operates in Biotechnology, Health Care and Pharmaceutical.

NantKwest has approximately 44 employees.

NantKwest has completed 3 funding rounds, raising a total of $103.50M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to NantKwest include Kuur Therapeutics, Verismo Therapeutics, Adicet Bio, Inc, Celularity Inc., 宜明昂科生物医药技术(上海)有限公司. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

NantKwest and Kuur Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About NantKwest

Funding Rounds & Investors (3)

NantKwest Alternatives & Competitors

FAQ About NantKwest